Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.

Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG; Adenoma Prevention with Celecoxib (APC) Study Investigators.

Cancer Prev Res (Phila). 2010 May;3(5):588-96. doi: 10.1158/1940-6207.CAPR-09-0271. Epub 2010 Apr 19.

2.

Celecoxib for the prevention of sporadic colorectal adenomas.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators.

N Engl J Med. 2006 Aug 31;355(9):873-84.

3.

Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET; Adenoma Prevention with Celecoxib Study Investigators.

Cancer Prev Res (Phila). 2009 Apr;2(4):310-21. doi: 10.1158/1940-6207.CAPR-08-0206. Epub 2009 Mar 31.

4.

Celecoxib for the prevention of colorectal adenomatous polyps.

Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP Trial Investigators.

N Engl J Med. 2006 Aug 31;355(9):885-95.

5.

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.

Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J; APC and PreSAP Trial Investigators.

Circulation. 2006 Sep 5;114(10):1028-35.

6.

Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention.

Thompson P, Roe DJ, Fales L, Buckmeier J, Wang F, Hamilton SR, Bhattacharyya A, Green S, Hsu CH, Chow HH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Martinez ME, Jacobs E, Ashbeck EL, Alberts DS, Lance P.

Cancer Prev Res (Phila). 2012 Dec;5(12):1381-93. doi: 10.1158/1940-6207.CAPR-12-0204. Epub 2012 Oct 11.

7.

C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.

Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2011 Aug;4(8):1172-80. doi: 10.1158/1940-6207.CAPR-10-0403.

8.

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators.

N Engl J Med. 2005 Mar 17;352(11):1071-80. Epub 2005 Feb 15.

9.

Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.

Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG; APC Trial Collaborators, Kubo M, Matsuda K, Dunlop M, Houlston RS, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Ratain MJ, Nakamura Y, Weiss ST, Tomlinson I, Bertagnolli MM.

Clin Cancer Res. 2013 Dec 1;19(23):6430-7. doi: 10.1158/1078-0432.CCR-13-0550. Epub 2013 Oct 1.

10.

The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.

Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2012 Jan;5(1):61-72. doi: 10.1158/1940-6207.CAPR-11-0337. Epub 2011 Oct 26.

11.

Aberrant crypt foci in the adenoma prevention with celecoxib trial.

Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, Gostout C, Eagle CJ, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2008 Jun;1(1):21-31. doi: 10.1158/1940-6207.CAPR-07-0011. Epub 2008 Apr 14.

12.

Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, Eagle CJ, Hawk ET, Bertagnolli MM.

Gastroenterology. 2009 Jun;136(7):2127-2136.e1. doi: 10.1053/j.gastro.2009.02.045. Epub 2009 Feb 21.

13.
14.

Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial.

Thompson PA, Ashbeck EL, Roe DJ, Fales L, Buckmeier J, Wang F, Bhattacharyya A, Hsu CH, Chow SH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Hamilton SR, Jacobs ET, Martinez EM, Alberts DS, Lance P.

J Natl Cancer Inst. 2016 Aug 16;108(12). pii: djw151. doi: 10.1093/jnci/djw151. Print 2016 Dec.

PMID:
27530656
15.

Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.

Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC; Familial Adenomatous Polyposis Study Group.

Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):920-7.

16.

Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.

Kraus S, Hummler S, Toriola AT, Poole EM, Scherer D, Kotzmann J, Makar KW, Kazanov D, Galazan L, Naumov I, Coghill AE, Duggan D, Gigic B, Arber N, Ulrich CM.

Pharmacogenet Genomics. 2013 Aug;23(8):428-437. doi: 10.1097/FPC.0b013e3283631784.

17.

Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial".

Stevens RG, Pretlow TP, Hurlstone DP, Giardina C, Rosenberg DW.

Cancer Prev Res (Phila). 2008 Aug;1(3):215-6; author reply 216. doi: 10.1158/1940-6207.CAPR-08-0094. No abstract available.

18.

Statin use and the risk of colorectal adenoma: A meta-analysis.

Jung YS, Park CH, Eun CS, Park DI, Han DS.

J Gastroenterol Hepatol. 2016 Nov;31(11):1823-1830. doi: 10.1111/jgh.13393.

PMID:
27043957
19.

Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.

Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F, Ueland PM, Greenberg ER; Polyp Prevention Study Group.

JAMA. 2007 Jun 6;297(21):2351-9.

PMID:
17551129
20.

Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.

Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB.

J Natl Cancer Inst. 2010 Dec 15;102(24):1835-44. doi: 10.1093/jnci/djq442. Epub 2010 Nov 29.

Supplemental Content

Support Center